source
- Ultragenyx to lay off roughly 20% of staff as it halts two rare disease drug programsUltragenyx announced it will cut about 20% of its workforce as it ends development of two rare disease drug candidates. The move follows a recent clinical study that failed to meet its primary end…
- CVS Health to split into two separate companies, separating insurance and pharmacy operationsCVS Health announced that it will divide the business into two independent companies. One entity will house its insurance arm Aetna together with pharmacy‑benefit manager Caremark, while the other…